UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

Diabetes/metabolism research and reviews, 2014-02, Vol.30 (2), p.104-119

2014

Volltextzugriff (PDF)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1489-1497

2012

Volltextzugriff (PDF)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Clinical pharmacokinetics, 2014-09, Vol.53 (9), p.787-800

2014

Volltextzugriff (PDF)

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

The New England journal of medicine, 2012-07, Vol.367 (4), p.319-328

2012

Volltextzugriff (PDF)

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Cochrane database of systematic reviews, 2020-11, Vol.11 (11), p.CD005613

2020

Volltextzugriff (PDF)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Volltextzugriff (PDF)

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Diabetic medicine, 2016-04, Vol.33 (4), p.471-477

2016

Volltextzugriff (PDF)

Cost‐effectiveness of long‐acting insulin analogues vs intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years

British journal of clinical pharmacology, 2020-05, Vol.86 (5), p.852-860

2020

Volltextzugriff (PDF)

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

Diabetes, obesity & metabolism, 2012-10, Vol.14 (10), p.944-950

2012

Volltextzugriff (PDF)

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

Journal of clinical pharmacology, 2014-07, Vol.54 (7), p.792-799

2014

Volltextzugriff (PDF)

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus

Cochrane database of systematic reviews, 2021-03, Vol.3 (4), p.CD013498

2021

Volltextzugriff (PDF)

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

Diabetic medicine, 2016-04, Vol.33 (4), p.497-505

2016

Volltextzugriff (PDF)

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

Diabetes care, 2013-09, Vol.36 (9), p.2536-2542

2013

Volltextzugriff (PDF)

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

Cochrane database of systematic reviews, 2007-04 (2), p.CD005613

2007

Volltextzugriff (PDF)

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Diabetes care, 2012-12, Vol.35 (12), p.2626-2630

2012

Volltextzugriff (PDF)

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Expert opinion on drug metabolism & toxicology, 2015, Vol.11 (8), p.1193-1201

2015

Volltextzugriff (PDF)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.261-267

2015

Volltextzugriff (PDF)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

Acta diabetologica, 2015-08, Vol.52 (4), p.649-662

2015

Volltextzugriff (PDF)

Comparative risks of diabetes‐related complications of basal insulins: a longitudinal population‐based cohort of type 1 diabetes 1999–2013 in Taiwan

British journal of clinical pharmacology, 2018-02, Vol.84 (2), p.379-391

2018

Volltextzugriff (PDF)

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1399-1408

2019

Volltextzugriff (PDF)

Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy

Journal of clinical pharmacology, 2015-12, Vol.55 (12), p.1369-1377

2015

Volltextzugriff (PDF)

Biosynthetic Human Insulin and Insulin Analogs

American journal of therapeutics, 2020-01, Vol.27 (1), p.e42-e51

2020

Volltextzugriff (PDF)

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

Current medical research and opinion, 2017-10, Vol.33 (10), p.1821-1831

2017

Volltextzugriff (PDF)

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial

Diabetes, obesity & metabolism, 2016-05, Vol.18 (5), p.500-507

2016

Volltextzugriff (PDF)

Molecular Engineering of Efficacious Mono-Valent Ultra-Long Acting Two-Chain Insulin-Fc Conjugates

Journal of medicinal chemistry, 2022-02, Vol.65 (3), p.2633-2645

2022

Volltextzugriff (PDF)

1 – 25 von 3.183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.636)
Mit Volltextzugriff
(2.207)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(2.685)
Science & Technology
(2.291)
Life Sciences & Biomedicine
(2.248)
Male
(1.572)
Female
(1.514)
Diabetes Mellitus, Type 2 - Drug Therapy
(1.317)
Insulin Glargine
(1.305)
Endocrinology & Metabolism
(1.225)
Insulin, Long-Acting
(1.224)
Hypoglycemic Agents - Therapeutic Use
(1.154)
Insulin - Analogs & Derivatives
(1.131)
Insulin
(1.088)
Middle Aged
(1.037)
Insulin - Therapeutic Use
(935)
Insulin, Long-Acting - Therapeutic Use
(911)
Adult
(889)
Hypoglycemic Agents - Administration & Dosage
(884)
Diabetes
(852)
Diabetes Mellitus, Type 1 - Drug Therapy
(823)
Insulin - Administration & Dosage
(737)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Cost‐effectiveness of long‐acting insulin analogues vs intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

Comparative risks of diabetes‐related complications of basal insulins: a longitudinal population‐based cohort of type 1 diabetes 1999–2013 in Taiwan

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy

Biosynthetic Human Insulin and Insulin Analogs

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial

Molecular Engineering of Efficacious Mono-Valent Ultra-Long Acting Two-Chain Insulin-Fc Conjugates

Suchergebnisse filtern